US Pharma MarketingOno to pay Biohaven $80M for protein degrader; UK pulls Valneva
Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer Tukysa label expansion; Novartis Rhapsido SD approval. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
Plus news about ADC Therapeutics, Atrium Therapeutics, Bristol Myers, Novartis and Pfizer.
Biohaven partners with Ono: Tokyo-based Ono Pharmaceutical has agreed to pay Biohaven $80 million upfront to license its pan-IgG ...
Source: Endpoints News